Last reviewed · How we verify

Corticosteroid Eye Drop

Ocugen · Phase 2 active Small molecule

Corticosteroid eye drops reduce inflammation in the eye by suppressing the immune system.

Corticosteroid eye drops reduce inflammation in the eye by suppressing the immune system. Used for Treatment of non-infectious uveitis affecting the posterior segment of the eye.

At a glance

Generic nameCorticosteroid Eye Drop
SponsorOcugen
Drug classCorticosteroid
ModalitySmall molecule
Therapeutic areaOphthalmology
PhasePhase 2

Mechanism of action

They do this by inhibiting the production of pro-inflammatory cytokines and other mediators of inflammation. This leads to a decrease in the number of inflammatory cells in the eye, which helps to reduce swelling and pain. Corticosteroids can also help to prevent scarring and promote healing in the eye.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: